G1 Therapeutics (GTHX) Reaches New 1-Year High and Low After Analyst Upgrade

G1 Therapeutics (NASDAQ:GTHX) shares hit a new 52-week high and low during mid-day trading on Friday after Needham & Company LLC raised their price target on the stock from $42.00 to $60.00. Needham & Company LLC currently has a buy rating on the stock. G1 Therapeutics traded as low as $52.76 and last traded at $51.49, with a volume of 3566 shares changing hands. The stock had previously closed at $50.94.

A number of other research analysts also recently issued reports on GTHX. BidaskClub raised G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, January 23rd. JPMorgan Chase increased their target price on G1 Therapeutics to $30.00 in a report on Monday, February 5th. Zacks Investment Research downgraded G1 Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 8th. BTIG Research reissued a “buy” rating and issued a $38.00 target price on shares of G1 Therapeutics in a report on Thursday, February 22nd. Finally, Cowen reissued a “buy” rating on shares of G1 Therapeutics in a report on Monday, March 5th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. G1 Therapeutics has an average rating of “Buy” and a consensus price target of $41.80.

Get G1 Therapeutics alerts:

In other news, VP Jennifer K. Moses sold 750 shares of the firm’s stock in a transaction dated Thursday, April 5th. The stock was sold at an average price of $37.47, for a total value of $28,102.50. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Mark A. Velleca sold 7,500 shares of the firm’s stock in a transaction dated Tuesday, May 15th. The stock was sold at an average price of $46.28, for a total value of $347,100.00. The disclosure for this sale can be found here. In the last three months, insiders sold 21,026 shares of company stock worth $843,033. 15.92% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of GTHX. Schwab Charles Investment Management Inc. bought a new position in shares of G1 Therapeutics in the third quarter worth about $364,000. California State Teachers Retirement System bought a new position in shares of G1 Therapeutics in the third quarter worth about $319,000. Alps Advisors Inc. raised its stake in shares of G1 Therapeutics by 13.1% in the fourth quarter. Alps Advisors Inc. now owns 31,409 shares of the company’s stock worth $623,000 after buying an additional 3,643 shares during the period. Hodges Capital Management Inc. bought a new position in shares of G1 Therapeutics in the fourth quarter worth about $292,000. Finally, Swiss National Bank bought a new position in shares of G1 Therapeutics in the fourth quarter worth about $286,000. 42.11% of the stock is currently owned by hedge funds and other institutional investors.

The company has a market capitalization of $1.61 billion and a P/E ratio of -14.26.

G1 Therapeutics (NASDAQ:GTHX) last released its earnings results on Thursday, May 3rd. The company reported ($0.70) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.07). equities analysts forecast that G1 Therapeutics will post -2.66 EPS for the current year.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer in the United States. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2a clinical trials for patients with small cell lung cancer, as well as Phase 2 clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; G1T38, an oral CDK4/6 inhibitor that is Phase 1b/2a clinical trials for the treatment of breast cancer; and G1T48, an oral selective estrogen receptor degrader, which is in preclinical development.